MALT1 inhibition is efficacious in both naïve and ibrutinib-resistant chronic lymphocytic leukemia

The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B cell receptor signaling, and most resistant cases carry mutations in BTK...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Res
Главные авторы: Saba, Nakhle S., Wong, Deanna H., Tanios, Georges, Iyer, Jessica R., Lobelle-Rich, Patricia, Dadashian, Eman L., Liu, Delong, Fontan, Lorena, Flemington, Erik K., Nichols, Cydney M., Underbayev, Chingiz, Safah, Hana, Melnick, Ari, Wiestner, Adrian, Herman, Sarah E. M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732856/
https://ncbi.nlm.nih.gov/pubmed/28993409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2485
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы